RxDoctor Payments Data

Nickolas Tomasic, MD

Urology · Culver City, CANPI 1104875160

Payments from drug & device makers

$5,552in general payments, 2019–2025

Across 198 payments — averaging $28.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$1K
  • Astellas Pharma US Inc$886
  • Johnson & Johnson$589
  • Pfizer$512
  • AbbVie$401
  • Sumitomo Pharma America, Inc.$234
  • plus $1K from 25 others

What the payments were for

  • Travel & lodging$72913%
  • Food & beverage$4,64284%
  • Education$1813%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,552 in reported general payments places this provider in the 65th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$174,035
Medicare patients
302
Services billed
38,905

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide19$287,400
OrgovyxRelugolix50$134,826
MyrbetriqMirabegron64$62,459
GemtesaVibegron34$45,438
Tolterodine Tartrate ErTolterodine Tartrate82$13,278
Alfuzosin Hcl ErAlfuzosin Hcl505$13,214
Tamsulosin Hcl699$9,715
Estradiol112$8,387
Methenamine Hippurate51$7,100
Dutasteride165$6,764
Finasteride433$5,635
Oxybutynin Chloride ErOxybutynin Chloride234$5,470
Testosterone13$4,536
NitrofurantoinNitrofurantoin Macrocrystal142$4,396
Fesoterodine Fumarate ErFesoterodine Fumarate27$3,367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$886$349,86083 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$234$180,26484 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,324 urology providers in California.

Other urology in Culver City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →